High-dose rifapentine for TB during pregnancy and breastfeeding
Rifapentine in High Doses in Pregnancy with TB (Radiant-Moms) study
This project looks at whether giving higher doses of the TB medicine rifapentine is acceptable and safe for pregnant and breastfeeding people with TB, including those living with HIV.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11173908 on NIH RePORTER |
What this research studies
You would be asked about your preferences and choices around TB treatment in pregnancy and breastfeeding using structured choice questions that present realistic treatment trade-offs. The team will use a discrete choice experiment (DCE) with pregnant and breastfeeding people and health care providers in TB-endemic countries to learn what matters most when picking a TB regimen. The work focuses on barriers to using a newer, shorter rifapentine-based regimen and on concerns about dosing and safety for mothers and babies. Results will be used to design future dosing and safety studies and to guide policy so pregnant and breastfeeding people can access appropriate TB options.
Who could benefit from this research
Good fit: Ideal participants are pregnant or breastfeeding people diagnosed with active TB (many may also be living with HIV), especially those living in TB-endemic regions in Africa and Asia.
Not a fit: People who are not pregnant or breastfeeding, do not have TB, or live outside the study countries are unlikely to benefit directly from this specific project.
Why it matters
Potential benefit: If successful, this work could help expand access to shorter rifapentine-based TB treatments for pregnant and breastfeeding people by informing safer dosing and policy decisions.
How similar studies have performed: Shorter rifapentine-based TB regimens have worked well in non-pregnant adults, but studies of high-dose rifapentine and use in pregnant and breastfeeding people are limited, so this approach addresses a new gap.
Where this research is happening
New York, United States
- Columbia University Health Sciences — New York, United States (Active)
Researchers
- Principal investigator: Hirsch-Moverman, Yael R — Columbia University Health Sciences
- Study coordinator: Hirsch-Moverman, Yael R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.